FUMOT Interview: Germany's Grey Market Shifts Online, '2+10' Products Emerge as Trend

Sep.20.2024
FUMOT Interview: Germany's Grey Market Shifts Online, '2+10' Products Emerge as Trend
FUMOT, a leading e-cigarette brand in Germany, shares market insights at InterTabac amid strict regulations and growing competition.

On September 19th, 2024, the InterTabac tobacco exhibition in Dortmund, Germany officially opened. On the opening day, 2Firsts conducted an exclusive interview with the popular e-cigarette brand FUMOT.

FUMOT Interview: Germany's Grey Market Shifts Online, '2+10' Products Emerge as Trend
FUMOT's best-selling product in Germany | Image source: 2Firsts

 

FUMOT staff briefed 2Firsts on the current situation in the German market. According to their information, leading brands in the compliant German market include ELFBAR, BLU, HQD, and FLERBAR. Additionally, FUMOT's flagship products have achieved shipments of several million units in the German market, making it their key market.

 

FUMOT Interview: Germany's Grey Market Shifts Online, '2+10' Products Emerge as Trend
FUMOT's new "2+10" products | Image source: 2Firsts

 

When discussing the mainstream product types in the German market, the staff member stated that due to factors such as low cost-effectiveness, small-sized disposable products have seen a significant decrease in market share in Germany, becoming increasingly marginalized. Conversely, new large-sized disposable products that comply with TPD standards are emerging, such as innovative products like "n in 1" and "2+10." Therefore, at this trade show, FUMOT also introduced a variety of innovative products like "2+10" to meet the demands of the German market and solidify its market position.

 

For brands looking to enter the German market, the staff member believes that although Germany is an important market in Europe with promising prospects, the acceptance of new brands is relatively low. Distributors tend to prefer familiar brands. Therefore, achieving success in the German market requires long-term cultivation and careful planning.

 

When it comes to regulation, the above-mentioned staff shared the regulatory situation of the e-cigarette market in Germany. According to their information, Germany imposes high taxes on e-liquid products, with a tax of 2 euros per compliant 10ml e-liquid. German police also conduct strict inspections of tax labels attached to products at the retail end. Among them, Berlin has the highest inspection frequency in the market, but the penalties for violations are relatively light, usually limited to confiscation of goods or fines. In contrast, the market in Cologne has the strictest regulation, and sellers of tax evasion products may face criminal liability.

 

According to reports, despite this, there are still underground markets in Germany, but these markets mainly operate through online channels such as WhatsApp and Instagram. Due to the high risks involved in offline transactions, only a few retail stores dare to get involved, and they usually only sell to trusted customers.

 

In the interview, FUMOT's onsite staff repeatedly mentioned the keyword "compliance." They believe that with the increasing strictness of market supervision in Germany, brands must actively align with compliance standards in order to achieve long-term stable development.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Japan Tobacco Inc. (JT) launched three limited-edition autumn tobacco sticks for its Ploom heated tobacco devices in Japan on October 16, 2026, under the EVO, MEVIUS and CAMEL brands. All three are regular tobacco variants with seasonal packaging. Each pack contains 20 sticks, priced at ¥620, ¥590 and ¥570, respectively, including tax. The products are compatible with all Ploom devices and are sold in limited quantities exclusively through the CLUB JT online store while supplies last.
product
Oct.20
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives